---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002858"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:39:21.197170+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M

## Summary
- ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.
- 2025 ARCALYST net product revenue guidance: $560M to $580M.
- Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.
- Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.
- Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months.

## SEC filing metadata
- accession: 0001104659-25-002858
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/0001104659-25-002858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/tm252986d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002858
- JSON: https://secwatch.observer/filing/0001104659-25-002858.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.